Article

COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants

2021-08-22

Abstract excerpt

As global vaccination campaigns against SARS-CoV-2 proceed, there is particular interest in the longevity of immune protection, especially with regard to increasingly infectious virus variants. Neutralizing antibodies (Nabs) targeting the receptor binding domain (RBD) of SARS-CoV-2 are promising correlates of protective immunity and have been successfully used for prevention and therapy. As SARS-CoV-2 variants of...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 49590bba-39a3-557c-b312-d5fb7d349dd4
DOI: 10.1101/2021.08.20.21262328

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutantsDOI 10.1101/2021.08.20.21262328Read

Antibody Fc-binding profiles and ACE2 affinity to SARS-CoV-2 RBD variants.Semantic proximity Read

Altered affinity to ACE2 and reduced Fc functional antibodies to SARS-CoV-2 RBD variantsSemantic proximity Read

Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay.Semantic proximity Read

Massively Multiplexed Affinity Characterization of Therapeutic Antibodies Against SARS-CoV-2 VariantsSemantic proximity Read

Titers of antibodies the receptor-binding domain (RBD) of ancestral SARS-CoV-2 are predictive for levels of neutralizing antibodies to multiple variantsSemantic proximity Read

Titers of antibodies the receptor-binding domain (RBD) of ancestral SARS-CoV-2 are predictive for levels of neutralizing antibodies to multiple variantsSemantic proximity Read

A bioluminescent and homogeneous SARS-CoV-2 spike RBD and hACE2 interaction assay for antiviral screening and monitoring patient neutralizing antibody levels.Semantic proximity Read

Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variantsSemantic proximity Read

Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variantsSemantic proximity Read

Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants.Semantic proximity Read

Comprehensive Mapping of Binding Hot Spots of SARS-CoV-2 RBD-specific Neutralizing Antibodies for Tracking Immune Escape VariantsSemantic proximity Read

ACE2-Fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concernSemantic proximity Read